A New Paradigm in Infectious Diseases Treatment & Prophylaxis Shaped by the Current Pandemic
The COVID-19 pandemic will end, or as any pandemic in the past, will lose its momentum. Yet, the precedents and the new paradigms formed in…
Webinar: Revisiting and Rebuilding Clinical Development of Drugs for Antimicrobial Resistance – Lessons Learned During the COVID-19 Pandemic
Join AMR experts from Medpace, IHMA, and GARDP as they discuss how we can use the momentum from the pandemic to rethink, rebuild and revitalize…
Infectious Diseases in the Immunocompromised Host
An in-depth look at infectious diseases including hematologic malignancies in immunocompromised patients and the unique challenges for clinical development.
Decreasing Timelines in Infectious Diseases Drug Development
Nothing derails a clinical study timeline more than poor planning and not anticipating and preparing for potential roadblocks. While you may not be able to…
The Potential Power of the Human Microbiome for Drug Development
The dynamic nature of the microbiome is driving momentum and enthusiasm for clinical research. Recent advances in analyzing the microbiome and how it impacts immunity…
New Whitepaper: The Microbiome in Clinical Trials – Opportunities and Challenges
Medpace and Diversigen discuss the opportunities and challenges of the microbiome in clinical trials in a recently published whitepaper. You can access the whitepaper in…
Q&A with Dr. Brian Murphy, VP of Medical Affairs for Infectious Diseases
In this post, Dr. Brian Murphy, Vice President of Medical Affairs for Infectious Diseases, discusses the following topic: “Source Control Review in Clinical Trials of…
The Promising Landscape of Microbiome-based Clinical Research
Recent discoveries have been made that have revealed the power of microbes to prevent, diagnose, and treat disease. As a result of these discoveries, clinical…